

Press Release 2018-12-14

Quickcool AB: Nomination Committee for Quickcool AB for the AGM 2019

In accordance with the decision taken at Quickcool AB Annual General Meeting on May 03, 2018, the nomination committee for the AGM 2019, shall consist of three members, who shall represent the two shareholders with the largest number of shares that are willing to be included in the nomination committee, and the Board's President. The nomination committee appoints the Chairman.

In accordance with the above guidelines, the nomination committee for the AGM 2019 will consist of the following persons:

1. Lennart Sjölund (Chairman of the Nomination Committee)
2. Mats Danielsson
3. Göran Brorsson (Chairman of the Board)

Together, the members of the nomination committee represent approximately 33 per cent of the shares in the company as of September 30, 2018.

The nomination committee shall prepare proposals for the following issues, to be presented at the AGM 2019 for decision:

- Proposal of Board members
- Proposal of Chairman of the Board
- Proposal of board fees
- Proposal of auditor and auditor's fee
- Proposal of Chairman of the AGM and
- Proposal of guidelines for the nomination committee for the AGM 2020

Shareholders who wish to submit proposals to the company's nomination committee can do so by e-mail to goran.brorsson@gbrpartners.se or by mail to the address:

Quickcool AB
Att: Valberedningen
Scheelevägen 17
223 70 Lund

The AGM for Quickcool AB will be held on Tuesday 7 May 2019.

For more information, please contact:

Fredrik Radencrantz, CEO
Phone: +46-46-286 38 40
E-mail: fredrik.radencrantz@quickcool.se

Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool's solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool's Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to: www.quickcool.se